Latest Kestrel Therapeutics News & Updates

See the latest news and media coverage for Kestrel. We track all announcements, press releases, and industry mentions in real time, all in one place.

Kestrel Therapeutics (Kestrel)

Biotechnology company developing KRAS-targeted cancer therapies

kestreltherapeutics.com

Headquarters: Watertown, United States
Company type: Private company
Number of employees: 20–50
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about Kestrel Therapeutics (Kestrel)

In short: Kestrel received FDA Fast Track designation for its pan-KRAS inhibitor and entered a $1.45 billion strategic agreement with AbbVie.

Company announcements

September 15 Kestrel

Kestrel receives FDA Fast Track designation for KST-6051

The designation applies to the pan-KRAS inhibitor treatment for advanced solid tumors in ongoing Phase 1 trials. This facilitates expedited review and frequent FDA communication.

April 29 Kestrel

Kestrel doses first patient in Phase 1 trial of KST-6051 KRAS inhibitor

The company also announced a strategic warrant agreement with AbbVie for up to $1.45 billion, including an exclusive acquisition option.

March 5 Kestrel

Kestrel announces FDA IND clearance for KST-6051

The Phase 1 trial FALCON will enroll patients with advanced KRAS-mutant solid tumors.

17 April 2025 Kestrel

Kestrel welcomes Ron Knickerbocker as new SVP of Data Sciences and Clinical Development

He brings extensive experience to the role, strengthening the Clinical Development team's capabilities.

Media coverage

September 15 Yahoo Finance

Kestrel Therapeutics Receives FDA Fast Track Designation for KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in the treatment of KRAS-Mutant Advanced Solid Tumors

WATERTOWN, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- ("Kestrel" or the "Company"), a clinical-stage biotechnology company developing next-generation small-molecule inhibitors targeting mutant KRAS, today announced...

August 24 Endpoints News

Option-to-acquire deals remain rare in biotech’s buzzy M&A season

J&J-Sail and AbbVie-Kestrel put a spotlight on the option-to-acquire structure — rare even in a record M&A year — with biotech and pharma leaders weighing...

March 6 Yahoo Finance

Kestrel Therapeutics Announces IND Clearance by U.S. FDA of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, Enabling Initiation of Phase 1 Trial

WATERTOWN, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Kestrel Therapeutics Inc. (“Kestrel” or the “Company”), a clinical stage biotechnology company developing next-generation small-molecule inhibitors ...

Never miss news about Kestrel

Track Kestrel and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Kestrel competitors & trending companies

Browse news for competitors to Kestrel and other trending companies.